Published in J Clin Psychiatry on April 01, 2003
Benefits of Switching Antidepressants Following Early Nonresponse | NCT00519012
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J Clin Psychiatry (2015) 1.51
Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci (2008) 0.95
Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry (2013) 0.94
Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl) (2014) 0.90
Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol (2007) 0.89
Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci (2009) 0.89
Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol (2008) 0.86
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci (2008) 0.85
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord (2010) 0.85
Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont) (2009) 0.84
Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. Psychiatry Res (2011) 0.82
Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder. BMC Psychiatry (2011) 0.78
Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. Int Clin Psychopharmacol (2011) 0.76
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals (Basel) (2010) 0.76
The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data. Eur Arch Psychiatry Clin Neurosci (2014) 0.76
Optimal use of antidepressants: when to act? J Psychiatry Neurosci (2009) 0.75
The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder. Asia Pac Psychiatry (2016) 0.75
Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. Am J Geriatr Psychiatry (2017) 0.75
[Pharmacological therapy for therapy-resistant depression. New developments]. Nervenarzt (2007) 0.75
Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ (2003) 3.78
Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr Genet (2006) 2.50
A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc (2003) 2.47
Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord (2004) 2.04
Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev (2011) 1.88
Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging (2005) 1.88
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol (2013) 1.55
Stimulus pulse-frequency-dependent efficacy and cognitive adverse effects of ultrabrief-pulse electroconvulsive therapy in patients with major depression. J ECT (2011) 1.42
Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord (2011) 1.41
Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol (2006) 1.38
Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. Gen Hosp Psychiatry (2004) 1.34
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
CNS manifestations of Fabry's disease. Lancet Neurol (2006) 1.29
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion (2004) 1.26
Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med (2007) 1.23
Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord (2007) 1.21
Empirical evaluation of the accuracy of diagnostic criteria for Restless Legs Syndrome. Sleep Med (2008) 1.18
Functional relevant loss of long association fibre tracts integrity in early Alzheimer's disease. Neuropsychologia (2007) 1.18
FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res (2007) 1.18
Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med (2008) 1.14
Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients' choice arm. Psychother Psychosom (2010) 1.14
Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging. Acta Paediatr Suppl (2007) 1.12
Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord (2010) 1.12
Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord (2007) 1.10
Screening for depression in primary care: will one or two items suffice? Eur Arch Psychiatry Clin Neurosci (2004) 1.10
Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm. Int J Neuropsychopharmacol (2009) 1.08
PLM detection by actigraphy compared to polysomnography: a validation and comparison of two actigraphs. Sleep Med (2008) 1.08
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med (2007) 1.06
Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Res (2006) 1.03
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis (2013) 1.01
Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol (2006) 1.00
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord (2004) 1.00
Can delusions be self-assessed? Concordance between self- and observer-rated delusions in schizophrenia. Psychiatry Res (2010) 0.99
Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry (2004) 0.99
Late structural alterations of cerebral white matter in long-term survivors of childhood leukemia. J Magn Reson Imaging (2008) 0.98
Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med (2010) 0.97
Pregabalin versus pramipexole for restless legs syndrome. N Engl J Med (2014) 0.96
Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res (2006) 0.95
Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology (2002) 0.94
Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord (2006) 0.93
Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage (2006) 0.93
Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts. Biol Psychiatry (2003) 0.92
Levodopa for restless legs syndrome. Cochrane Database Syst Rev (2011) 0.92
Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J Neurol (2010) 0.91
European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol (2012) 0.91
Efficacy and safety of dopamine agonists in restless legs syndrome. Sleep Med (2012) 0.91
Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study. Health Qual Life Outcomes (2011) 0.91
Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings. J Alzheimers Dis (2011) 0.90
Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med (2007) 0.90
Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry (2003) 0.90
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry (2008) 0.89
Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol (2005) 0.89
Valproic Acid and hypersensitivity syndrome. Am J Psychiatry (2004) 0.88
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet (2007) 0.88
One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med (2008) 0.88
Is a shared decision-making approach effective in improving hypertension management? J Clin Hypertens (Greenwich) (2009) 0.88
Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol (2011) 0.87
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol (2010) 0.87
Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci (2009) 0.87
Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit (2004) 0.87
Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol (2006) 0.86
Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenet Genomics (2009) 0.86
Improvement in refractory obsessive compulsive disorder with dronabinol. Am J Psychiatry (2008) 0.86
Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry (2007) 0.86
Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiatry (2010) 0.86
Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol (2009) 0.86
The influence of daytime napping versus controlled activity on the subjective well-being of patients with major depression. Psychiatry Res (2012) 0.85
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord (2007) 0.85
CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type. J Geriatr Psychiatry Neurol (2008) 0.84
Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem (2005) 0.84
Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. J Clin Psychiatry (2004) 0.84
Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep (2004) 0.84
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol (2010) 0.84
Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med (2014) 0.84
Integration of complementary and alternative medicine into German medical school curricula -- contradictions between the opinions of decision makers and the status quo. Forsch Komplementarmed Klass Naturheilkd (2005) 0.82
Haplotypes of dopamine and serotonin transporter genes are associated with antisocial personality disorder in alcoholics. Psychiatr Genet (2010) 0.82
A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.82
One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord (2003) 0.82
Successful treatment of blepharitis with bibrocathol (Posiformin® 2 %). Graefes Arch Clin Exp Ophthalmol (2012) 0.81
Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal-induced seizures and delirium tremens. Eur Arch Psychiatry Clin Neurosci (2004) 0.81
Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. Ther Drug Monit (2013) 0.81
Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG). Mov Disord (2007) 0.81
Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. World J Biol Psychiatry (2010) 0.81
Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. J Sleep Res (2002) 0.81
Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat (2008) 0.81
Cognitive behavioural therapy in elderly type 2 diabetes patients with minor depression or mild major depression: study protocol of a randomized controlled trial (MIND-DIA). BMC Geriatr (2010) 0.81
Declarative and procedural memory consolidation during sleep in patients with borderline personality disorder. J Psychiatr Res (2007) 0.80
Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. J Inherit Metab Dis (2011) 0.80